Respiratory syncytial virus (RSV) vaccine
The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.
1. A method of treatment or prophylaxis of Respiratory syncytial virus (RSV) infections comprising the steps:
a) Providing the mRNA sequence encoding at least one antigenic polypeptide from the fusion protein F, the nucleoprotein N, the M2-1 protein or the M2-2 protein of RSV, wherein the G/C content of the sequence encoding the antigenic polypeptide is increased compared with the G/C content of the coding region of the wild type mRNA encoding an antigenic polypeptide; and
b) applying or administering the mRNA sequence to a subject;
wherein the mRNA sequence encoding the antigenic polypeptide comprises a sequence at least 90% identical to one of Seq. Id. Nos. 31, 32, 33, 34, or 35.
2. The method according to claim 1 , wherein the mRNA further comprising a 5′-cap structure, a poly(A) sequence, and/or a poly(C) sequence.
3. The method according to claim 2 , wherein the 5′cap structure is m7GpppN.
4. The method according to claim 2 , wherein the poly(A) sequence comprises a sequence of 25 to 400 adenosine nucleotides.
5. The method according to claim 1 , wherein the mRNA further comprises at least one histone stem-loop.
6. The method according to claim 1 , wherein the mRNA sequence further comprises a stabilizing sequence from the alpha globin 3′ UTR, positioned 3′ relative to the coding region of the mRNA sequence.
7. The method according to claim 1 , wherein the mRNA sequence comprises from a 5′ to 3′: a 5′-cap structure, a 5′ UTR sequence, the sequence encoding the at least one antigenic polypeptide, a 3′ UTR, a poly(A) sequence, a poly(C) sequence and a histone stem-loop sequence.
8. The method according to claim 1 , wherein the at least one antigenic polypeptide is from the RSV fusion protein F.
9. The method according to claim 1 , wherein the mRNA sequence is complexed with a cationic or polycationic compound.
10. The method according to claim 9 , wherein the cationic or polycationic compound is protamine, poly-L-lysine (PLL), or poly-arginine.
11. The method according to claim 9 , wherein the cationic or polycationic compound is protamine.
12. The method according to claim 9 , wherein the weight ratio of the mRNA sequence to the cationic or polycationic compound is in the range from 6:1 to 0.25:1.
13. The method of claim 1 , wherein the mRNA sequence is administered by injection.
14. The method of claim 13 , wherein the mRNA sequence is administered by intradermal or intramuscular injection.
15. The method of claim 1 , wherein the mRNA sequence is formulated in a Ringer's lactate solution.
16. The method of claim 1 , further comprising administering mRNA sequences encoding at least 2 different antigenic polypeptides from RSV.
17. The method of claim 16 , wherein the mRNA sequences encoding the at least 2 different antigenic polypeptides are administered separately.
18. The method of claim 16 , wherein the mRNA sequences encoding the at least 2 different antigenic polypeptides are administered in the same formulation.
19. The method according to claim 1 , wherein the mRNA sequence encoding the antigenic polypeptide comprises a sequence at least 95% identical to SEQ ID NO: 31, 32, 33, 34 or 35.
20. The method according to claim 19 , wherein the mRNA sequence encoding the antigenic polypeptide comprises a sequence according to SEQ ID NO: 31, 32, 33, 34 or 35.
21. The method of claim 1 , further defined as method for inducing RSV-specific T-cell response in the subject.